SHERIDAN, WYOMING – May 7, 2025 – Edwards Lifesciences (NYSE: EW), a global leader in structural heart innovation, has announced its financial results for the first quarter ended March 31, 2025. The company delivered impressive growth across key product categories, including Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral and Tricuspid Therapies (TMTT), positioning itself for continued success in the structural heart market.
Strong Sales Growth Drives First Quarter Results
In Q1 2025, Edwards Lifesciences reported total sales of $1.41 billion, reflecting a robust 6.2% increase year-over-year, or 7.9% on an adjusted basis. The company also posted a solid earnings per share (EPS) of $0.622, with adjusted EPS of $0.64, reinforcing its strong financial position.
TAVR sales accounted for a significant portion of this growth, reaching $1.05 billion, a 3.8% increase from the previous year. Constant currency sales grew by 5.4%, surpassing expectations. Edwards continues to see strong demand for its SAPIEN 3 Ultra RESILIA platform, particularly in the United States, where hospitals are scaling their capabilities to meet increasing procedure volumes.
Exceptional Growth in TMTT Portfolio
Edwards' Transcatheter Mitral and Tricuspid Therapies (TMTT) segment delivered impressive results in Q1 2025. TMTT sales grew by 58%, totaling $115 million, driven by strong adoption of the PASCAL and EVOQUE devices. The company's TMTT portfolio is uniquely positioned to address the diverse needs of patients with tricuspid and mitral valve diseases.
Edwards also announced the CE Mark approval of the SAPIEN M3, the world’s first transcatheter mitral valve replacement system. This approval further solidifies Edwards’ leadership in the TMTT space and provides new treatment options for patients suffering from mitral regurgitation, a condition with limited therapeutic alternatives.
Surgical and Global Expansion
Edwards’ surgical portfolio also showed positive momentum, with global sales of $251 million in Q1 2025, marking a 1% increase over the previous year. The company’s premium RESILIA tissue portfolio, including MITRIS, INSPIRIS, and KONECT, continues to drive adoption in key global markets, including China, where MITRIS launched to positive surgeon feedback.
In addition, Edwards remains committed to expanding access to life-saving treatments in underpenetrated regions. In Japan, Edwards is addressing the growing need for aortic stenosis treatment among the elderly population, while in Europe, the SAPIEN 3 Ultra RESILIA is gaining traction.
Strong Financial Outlook for 2025
Edwards has raised its 2025 sales guidance to $5.7 to $6.1 billion, reflecting a $100 million increase due to favorable foreign exchange rates. The company has also raised its TMTT sales guidance to $530 million to $550 million, driven by strong business momentum. Despite expected pressures on operating margins from tariffs and the JenaValve acquisition, Edwards is confident in its ability to manage costs and maintain a solid operating margin of 27% to 28%.
Bernard Zovighian, CEO of Edwards Lifesciences, commented, "The many milestones achieved this quarter are the result of our structural heart-focused strategy and our decades of unwavering dedication to driving breakthrough innovation. We are pleased with our strong start to the year and have confidence in our 2025 outlook."
Conclusion
Edwards Lifesciences' strong Q1 performance underscores its leadership in the structural heart industry and its commitment to delivering life-changing innovations. With robust growth in TAVR and TMTT, as well as promising new approvals and product launches, Edwards is poised for continued success in 2025.
Learn more at www.edwards.com.